{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:54:53Z","timestamp":1793213693324,"version":"4.5.0"},"reference-count":88,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma, leukemia, and multiple myeloma. Treatment in these settings has resulted in durable response rates as high at 80%-90%. These findings have not been replicated in clinical trials of solid tumor malignancies because of the complex tumor microenvironment, antigen heterogeneity, and immunosuppressive mechanisms that hinder antitumor T-cell responses in solid tumors. Several strategies are being investigated and have proven successful in overcoming these hurdles. This paper provides an overview of the current landscape of autologous T-cell therapies, with a particular focus on their use as treatments for refractory solid tumor malignancies, highlighting promising targets being investigated in ongoing clinical trials and toxicities associated with these therapeutic approaches.<\/jats:p>","DOI":"10.1200\/edbk-25-473440","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:59:38Z","timestamp":1748548778000},"source":"Crossref","is-referenced-by-count":10,"title":["Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities"],"prefix":"10.1200","volume":"45","author":[{"given":"Daniel","family":"Reinhorn","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn S.","family":"Tak","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D'Angelo","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola A.","family":"Fashoyin-Aje","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01115-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.12.004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0568"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3803"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0378"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28312"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1045024"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188701"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08171-9"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00753-0"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2007.10.018"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2782"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.01.006"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2"},{"key":"e_1_3_3_30_2","unstructured":"US Food and Drug Administration package insert\u2014VYLOY. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761365s000lbl.pdf"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02314"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12316"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04433-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02452-y"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"e_1_3_3_40_2","unstructured":"US Food and Drug Administration\u2014TECELRA approval letter. https:\/\/www.fda.gov\/media\/180568\/download?attachment"},{"key":"e_1_3_3_41_2","unstructured":"US Food and Drug Administration package insert\u2014TECELRA. https:\/\/www.fda.gov\/media\/180565\/download?attachment"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211714"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"key":"e_1_3_3_45_2","first-page":"A788","article-title":"687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients","volume":"12","author":"Wermke M","year":"2024","unstructured":"Wermke M, Alsdorf W, Araujo DM, et al: 687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients. J Immunother Cancer 12:A788, 2024 (suppl 2)","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0762-2"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32491-x"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","unstructured":"D'Angelo SP Druta M Van Tine BA et al: Letetresgene autoleucel in advanced\/metastatic myxoid\/round cell liposarcoma. J Clin Oncol 10.1200\/JCO-24-01466 [epub ahead of print on January 21 2025]","DOI":"10.1200\/JCO-24-01466"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2500"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8650","article-title":"AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8\u03b1\/\u03b2 coreceptor, and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors","volume":"42","author":"Mitchell S","year":"2024","unstructured":"Mitchell S, Khan B, Payumo F, et al: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8\u03b1\/\u03b2 coreceptor, and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors. J Clin Oncol 42, 2024 (suppl 16; abstr TPS8650)","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2677","article-title":"An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02\u2013positive adult patients with unresectable, advanced, and\/or metastatic solid tumors that are positive for the KRAS G12D mutation","volume":"42","author":"Punekar SR","year":"2024","unstructured":"Punekar SR, Pelster M, Becerra CR, et al: An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02\u2013positive adult patients with unresectable, advanced, and\/or metastatic solid tumors that are positive for the KRAS G12D mutation. J Clin Oncol 42, 2024 (suppl 16; abstr TPS2677)","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2158"},{"key":"e_1_3_3_55_2","article-title":"Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer","volume":"41","author":"Murphy MAB","year":"2023","unstructured":"Murphy MAB, Ajani JA, Van Tine BA, et al: Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer. J Clin Oncol 41, 2023 (suppl 4; abstr 349)","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.01.187"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS708"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.417"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0041"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2538"},{"key":"e_1_3_3_66_2","first-page":"A486","article-title":"First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)","volume":"9","author":"Schoenfeld A","year":"2021","unstructured":"Schoenfeld A, Lee S, Paz-Ares L, et al: First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). J Immunother Cancer 9:A486-A487, 2021 (suppl 2)","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005847"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03627-5"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","unstructured":"Mulvey A Trueb L Coukos G et al: Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov 10.1038\/s41573-024-01100-5 [epub ahead of print on February 3 2025]","DOI":"10.1038\/s41573-024-01100-5"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00704-3"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2034-7"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.794183"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05703-9"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.60"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac163"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2128"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"e_1_3_3_88_2","unstructured":"US Food and Drug Administration package insert\u2014AMTAGVI. https:\/\/www.fda.gov\/media\/176417\/download?attachment"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","unstructured":"The road to CAR-T-cell therapy for lethal childhood brain tumours. Nature 10.1038\/d41586-024-04156-w [epub ahead of print on January 15 2025]","DOI":"10.1038\/d41586-024-04156-w"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:59:51Z","timestamp":1748548791000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473440"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473440","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473440"}}